Drugs / SPS4251
last change Jul 2013 re-read 2 minutes ago

SPS4251

Developed for
psoriasis
Investigated by
Bioskin GmbH · Circassia Limited

Trials 1 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01743118 Mar → Jul 2013 psoriasis Circassia Limited Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SPS4251 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01743118
Action Inhibit “selective blockers of a lymphocyte potassium channel” NCT01743118
Route Topical “will be topically applied” NCT01743118